DODouglas Osei-Hyiaman

Douglas Osei-Hyiaman

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Douglas Osei-Hyiaman has a total of 180 co-authors. Here are the top co-authors by number of shared publications:

  • George Kunos

    Laboratory of Physiologic Studies, National Institute on Alcohol Abuse and Alcoholism (NIAAA), NIH, Bethesda, Maryland, USA

    14 shared publications
  • Jie Liu

    Laboratory of Physiologic Studies , National Institute on Alcohol Abuse and Alcoholism of the National Institutes of Health, 5625 Fishers Lane, RM 2S-18, MSC-9413, Bethesda, Maryland 20892-9413, U.S.A.

    12 shared publications
  • Sándor Bátkai

    Laboratory of Physiologic Studies, National Institute on Alcohol Abuse and Alcoholism, National Institutes of Health, 5625 Fishers Lane, Rockville, MD 20852, USA

    10 shared publications
  • Pal Pacher

    Laboratory of Cardiovascular Physiology and Tissue Injury, National Institute on Alcohol Abuse and Alcoholism, National Institutes of Health , 5625 Fishers Lane Rockville, Bethesda, MD 20852

    9 shared publications
  • George Kunos

    8 shared publications
  • Judith Harvey-White

    Laboratory of Physiologic Studies , National Institute on Alcohol Abuse and Alcoholism of the National Institutes of Health, 5625 Fishers Lane, RM 2S-18, MSC-9413, Bethesda, Maryland 20892-9413, U.S.A.

    8 shared publications

Latest Publications

  • Open Access

    Schistosoma haematobium infection is associated with alterations in energy and purine-related metabolism in preschool-aged children

    by Derick N. M. Osakunor, Takafira Mduluza, Douglas Osei-Hyiaman, Karl Burgess, Mark E. J. Woolhouse, Francisca Mutapi

    Helminths are parasitic worms that infect over a billion people worldwide. The pathological consequences from infection are due in part, to parasite-induced changes in host metabolic pathways. Here, we analyse the changes in host metabolic profiles, in response to the firstSchistosoma haematobiuminfection and treatment in Zimbabwean children. A cohort of 83 schistosome-negative children (2–5 years old) as determined by parasitological examination, guardian interviews and examination of medical records, was recruited at baseline. Children were followed up after three months for parasitological diagnosis of their firstS.haematobiuminfection, by detection of parasite eggs excreted in urine. Children positive for infection were treated with the antihelminthic drug praziquantel, and treatment efficacy checked three months after treatment. Blood samples were taken at each time point, and capillary electrophoresis mass spectrometry in conjunction with multivariate analysis were used to compare the change in serum metabolite profiles in schistosome-infected versus uninfected children. Following baseline at the three-month follow up, 11 children had become infected withS.haematobium(incidence = 13.3%). Our results showed that infection withS.haematobiumwas associated with significant increases (>2-fold) in discriminatory metabolites, linked primarily with energy (G6P, 3-PG, AMP, ADP) and purine (AMP, ADP) metabolism. These observed changes were commensurate with schistosome infection intensity, and levels of the affected metabolites were reduced following treatment, albeit not significantly. This study demonstrates that early infection withS.haematobiumis associated with alterations in host energy and purine metabolism. Taken together, these changes are consistent with parasite-related clinical manifestations of malnutrition, poor growth and poor physical and cognitive performance observed in schistosome-infected children.


  • Open Access

    Plasma metabolome analysis of patients with major depressive disorder

    by Noriyuki Kawamura, Kosaku Shinoda, Hajime Sato, Kazunori Sasaki, Makoto Suzuki, Kumi Yamaki, Tamaki Fujimori, Hiroyuki Yamamoto, Douglas Osei‐Hyiaman, Yoshiaki Ohashi

    Aim: This study sought to characterize the plasma metabolite profiling of patients with major depressive disorder (MDD).Methods: Psychiatric assessments were made with the Structured Clinical Interview for DSM‐IV Axis I Disorders. In the exploratory cohort, plasma metabolite profiles of 34 MDD patients and 31 mentally healthy controls were compared using capillary electrophoresis‐mass spectrometry. Among the candidate metabolites, we focused on a metabolite showing the largest difference. The absolute concentrations were measured in two cohorts from a psychiatric primary care clinic to characterize the accuracy of the metabolite biomarker.Results: Among 23 metabolites significantly lower in the MDD group than in healthy controls, we focused on phosphoethanolamine (PEA) as a candidate. The reduction of PEA levels in MDD was checked in independent clinical sample sets. An ion‐chromatography‐fluorescence detection method was developed to measure plasma PEA levels. In the preliminary cohort, we examined 34 MDD and 43 non‐MDD subjects. The area under the receiver–operator curve (AUC) was 0.92, with sensitivity/specificity greater than 88%, at a cut‐off of 1.46 μM. In the checking cohort, with 10 MDD and 13 non‐MDD subjects, AUC was 0.89, with sensitivity/specificity of 86% and 100%, respectively, at a cut‐off of 1.48 μM. Plasma PEA inversely correlated with MDD severity, depressed mood, loss of interest, and psychomotor retardation.Conclusion: These results suggest that plasma PEA level could be a candidate biomarker of MDD in the clinical setting. Further studies comparing MDD and mentally healthy controls are needed to confirm the utility of PEA as a biomarker for depression.


  • Open Access

    Mice lacking GPR3 receptors display late-onset obese phenotype due to impaired thermogenic function in brown adipose tissue

    by Grzegorz Godlewski, Tony Jourdan, Gergő Szanda, Joseph Tam, Resat Cinar, Judith Harvey-White, Jie Liu, Bani Mukhopadhyay, Pál Pacher, Fong Ming Mo, et al.

    We report an unexpected link between aging, thermogenesis and weight gain via the orphan G protein-coupled receptor GPR3. Mice lacking GPR3 and maintained on normal chow had similar body weights during their first 5 months of life, but gained considerably more weight thereafter and displayed reduced total energy expenditure and lower core body temperature. By the age of 5 months GPR3 KO mice already had lower thermogenic gene expression and uncoupling protein 1 protein level and showed impaired glucose uptake into interscapular brown adipose tissue (iBAT) relative to WT littermates. These molecular deviations in iBAT of GPR3 KO mice preceded measurable differences in body weight and core body temperature at ambient conditions, but were coupled to a failure to maintain thermal homeostasis during acute cold challenge. At the same time, the same cold challenge caused a 17-fold increase in Gpr3 expression in iBAT of WT mice. Thus, GPR3 appears to have a key role in the thermogenic response of iBAT and may represent a new therapeutic target in age-related obesity.


  • Open Access

    Biologically active, high levels of interleukin-22 inhibit hepatic gluconeogenesis but do not affect obesity and its metabolic consequences

    by Ogyi Park, Sung Hwan Ki, Mingjiang Xu, Hua Wang, Dechun Feng, Joseph Tam, Douglas Osei-Hyiaman, George Kunos, Bin Gao

    Interleukin-22 (IL-22), a cytokine with important functions in anti-microbial defense and tissue repair, has been recently suggested to have beneficial effects in obesity and metabolic syndrome in some but not in other studies. Here, we re-examined the effects of IL-22 on obesity, insulin resistance, and hepatic glucose metabolism. Genetic deletion of IL-22 did not affect high-fat-diet (HFD)-induced obesity and insulin resistance. IL-22 transgenic mice with relatively high levels of circulating IL-22 (~600 pg/ml) were completely resistant to Concanavalin A-induced liver injury but developed the same degree of high fat diet (HFD)-induced obesity, insulin resistance, and fatty liver as the wild-type littermate controls. Similarly, chronic treatment with recombinant mouse IL-22 (rmIL-22) protein did not affect HFD-induced obesity and the associated metabolic syndrome. In vivo treatment with a single dose of rmIL-22 downregulated the hepatic expression of gluconeogenic genes and subsequently inhibited hepatic gluconeogenesis and reduced blood glucose levels both in HFD-fed and streptozotocin (STZ)-treated mice without affecting insulin production. In vitro exposure of mouse primary hepatocytes to IL-22 suppressed glucose production and the expression of gluconeogenic genes. These inhibitory effects were partially reversed by blocking STAT3 or the AMPK signaling pathway. Biologically active, high levels of IL-22 do not affect obesity and the associated metabolic syndrome. Acute treatment with IL-22 inhibits hepatic gluconeogenesis, which is mediated via the activation of STAT3 and AMPK in hepatocytes.


  • Open Access

    Dietary Linoleic Acid Elevates Endogenous 2‐AG and Anandamide and Induces Obesity

    by Anita R. Alvheim, Marian K. Malde, Douglas Osei‐Hyiaman, Yu Hong Hong, Robert J. Pawlosky, Lise Madsen, Karsten Kristiansen, Livar Frøyland, Joseph R. Hibbeln

    Suppressing hyperactive endocannabinoid tone is a critical target for reducing obesity. The backbone of both endocannabinoids 2‐arachidonoylglycerol (2‐AG) and anandamide (AEA) is the ω‐6 fatty acid arachidonic acid (AA). Here we posited that excessive dietary intake of linoleic acid (LA), the precursor of AA, would induce endocannabinoid hyperactivity and promote obesity. LA was isolated as an independent variable to reflect the dietary increase in LA from 1 percent of energy (en%) to 8 en% occurring in the United States during the 20th century. Mice were fed diets containing 1 en% LA, 8 en% LA, and 8 en% LA + 1 en% eicosapentaenoic acid (EPA) + docosahexaenoic acid (DHA) in medium‐fat diets (35 en% fat) and high‐fat diets (60 en%) for 14 weeks from weaning. Increasing LA from 1 en% to 8 en% elevated AA‐phospholipids (PL) in liver and erythrocytes, tripled 2‐AG + 1‐AG and AEA associated with increased food intake, feed efficiency, and adiposity in mice. Reducing AA‐PL by adding 1 en% long‐chain ω‐3 fats to 8 en% LA diets resulted in metabolic patterns resembling 1 en% LA diets. Selectively reducing LA to 1 en% reversed the obesogenic properties of a 60 en% fat diet. These animal diets modeled 20th century increases of human LA consumption, changes that closely correlate with increasing prevalence rates of obesity. In summary, dietary LA increased tissue AA, and subsequently elevated 2‐AG + 1‐AG and AEA resulting in the development of diet‐induced obesity. The adipogenic effect of LA can be prevented by consuming sufficient EPA and DHA to reduce the AA‐PL pool and normalize endocannabinoid tone.


  • Fasting Co-Suppresses Nesfatin-1 and GPR12 in Mouse Hypothalamic Appetite Center: Implications for Energy Metabolism

    by Douglas Osei-Hyiaman, Lena Sophie-Dreher, Seiichiro Nishimura, Jeffrey Encinas

    Nesfatin-1 is a recently discovered endogenous satiety peptide that is cleaved from its precursor nucleobindin-2 (NUCB2) by prohormone convertase. Nesfatin-1 and its precursor, NUCB2 are expressed in the hypothalamus and in peripheral tissues and are both regulated by nutritional status. Circulating nesfatin-1 levels change with metabolic state, showing significant inverse correlations with BMI and body fat mass when sampled after fasting. There is currently no known cognate receptor for nesfatin-1, nor have the pharmacology or signaling mechanisms related to its role in satiety been established yet. Here we show that 24-hour fasting suppresses both nesfatin-1 and the orphan G-protein coupled receptor GPR12 immunoreactivity in mouse hypothalamus (PVN, LH, DMD, ArC, ME, PeVN, and VMH) and that these effects in both cases can be reversed by feeding. Although a direct interaction between the peptide and GPR12 has not been demonstrated, our findings indicate that both GPR12 and endogenous nesfatin-1 may be regulated coordinately by changes in metabolic state. Further studies are underway to identify a possible relationship. Nothing to Disclose: DO-H, LS-D, SN, JE


  • Inhibitor of Fatty Acid Amide Hydrolase Normalizes Cardiovascular Function in Hypertension without Adverse Metabolic Effects

    by Grzegorz Godlewski, Shakiru O. Alapafuja, Sándor Bátkai, Spyros P. Nikas, Resat Cinar, László Offertáler, Douglas Osei-Hyiaman, Jie Liu, Bani Mukhopadhyay, Judith Harvey-White, et al.


  • Open Access

    Peripheral CB1 cannabinoid receptor blockade improves cardiometabolic risk in mouse models of obesity

    by Joseph Tam, V. Kiran Vemuri, Jie Liu, Sándor Bátkai, Bani Mukhopadhyay, Grzegorz Godlewski, Douglas Osei-Hyiaman, Shinobu Ohnuma, Suresh V. Ambudkar, James Pickel, et al.


  • Top Cited Papers
    Open Access

    Peripheral CB1 cannabinoid receptor blockade improves cardiometabolic risk in mouse models of obesity

    by Joseph Tam, V. Kiran Vemuri, Jie Liu, Sándor Bátkai, Bani Mukhopadhyay, Grzegorz Godlewski, Douglas Osei-Hyiaman, Shinobu Ohnuma, Suresh V. Ambudkar, James Pickel, et al.

    Obesity and its metabolic consequences are a major public health concern worldwide. Obesity is associated with overactivity of the endocannabinoid system, which is involved in the regulation of appetite, lipogenesis, and insulin resistance. Cannabinoid-1 receptor (CB1R) antagonists reduce body weight and improve cardiometabolic abnormalities in experimental and human obesity, but their therapeutic potential is limited by neuropsychiatric side effects. Here we have demonstrated that a CB1R neutral antagonist largely restricted to the periphery does not affect behavioral responses mediated by CB1R in the brains of mice with genetic or diet-induced obesity, but it does cause weight-independent improvements in glucose homeostasis, fatty liver, and plasma lipid profile. These effects were due to blockade of CB1R in peripheral tissues, including the liver, as verified through the use of CB1R-deficient mice with or without transgenic expression of CB1R in the liver. These results suggest that targeting peripheral CB1R has therapeutic potential for alleviating cardiometabolic risk in obese patients.


  • Open Access

    Transcriptional Regulation of Cannabinoid Receptor-1 Expression in the Liver by Retinoic Acid Acting via Retinoic Acid Receptor-γ

    by Bani Mukhopadhyay, Jie Liu, Douglas Osei-Hyiaman, Grzegorz Godlewski, Partha Mukhopadhyay, Lei Wang, Won-Il Jeong, Bin Gao, Gregg Duester, Ken Mackie, et al.